Interpace Biosciences Q1 2026 revenue $9.0M, thyroid revenue up 12% YoY; reaffirms 16% growth guidance

INTERPACE BIOSCIENCES, INC.

2026-Q1 EPS reported $0.03 revenue$9,032,000

Q1 revenue $9.0M; GAAP down 22% YoY due to PancraGEN exit, but Pro Forma revenue up 14% to $9.0M from $7.9M.
Adjusted EBITDA $1.6M (17% margin) vs $0.8M Pro Forma in prior year; operating income margin improved to 12% from 6% Pro Forma.
Thyroid test volume increased 10% YoY; revenue per test up 3%; active accounts increased 5%.
Gross margin expanded to 65% from 59% Pro Forma; company debt-free with $8.7M cash collections in Q1.
Reaffirmed 2026 guidance of ~16% year-over-year thyroid revenue growth.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

INTERPACE BIOSCIENCES, INC. reported first quarter ended March 31, 2026 results: revenue $9.0 million, net income $0.8 million. Guidance reaffirmed.

Period: first quarter ended March 31, 2026
Revenue: $9.0 million
Net income: $0.8 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Interpace generated Q1 2026 revenue of $9.0 million on 12% year-over-year thyroid revenue growth, delivered $0.8 million of income from continuing operations

View on SEC.gov

Browse all earnings releases →

INTERPACE BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0001493152-26-023095

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.